In a multi-target drug discovery collaboration, Prellis Biologics has teamed up with Eli Lilly and Company to develop high-quality, next-generation antibodies. This strategic partnership will leverage Prellis' unique EXIS and AntiGen AI platforms, which combine a rapid organoid system with artificial intelligence. The goal is to accelerate the discovery of highly diverse and fully human antibodies for multiple disease targets.

The collaboration's key feature is Prellis' proprietary lymph node organoid technology, which can rapidly replicate a human immune response in a lab setting, coupled with AI-based optimization to enhance therapeutic efficacy, safety, and manufacturability. Under the agreement, Prellis will receive an up-front payment, along with development and sales milestones, and royalties on any licensed antibodies. According to Mike Nohaile, CEO of Prellis, the company's platform is unique because it combines a living biological system—human lymph node organoids—with generative AI refinements. This "biological AI" approach addresses a major limitation in drug development by providing vast quantities of high-quality, fully human training data for novel targets. The system continuously improves drug candidates through feedback loops. Prellis' chief scientific officer, Les Miranda, stated that the company's mission is to transform how antibody-based therapies are developed to create more precise, effective, and accessible candidates. The collaboration with Lilly highlights Prellis' vision to replace previous drug discovery methods with a more versatile and scalable bio-AI hybrid that synergistically converges biology and artificial intelligence to address complex diseases faster.